צמיחת הכנסות ב-12 חודשים נגררים: Lixte Biotechnology, Inc. (LIXT)

Lixte Biotechnology is developing a network for creating LB-100 inhibitors through strategic alliances with scientific centers, while the success of its cancer therapy relies on medical efficacy rather than market cycles. This rolling annual sales growth chart reflects revenue dynamics, where the indicator value stands at 0.00. The company is currently funding early-stage tests using its existing cash reserves.
Lixte Biotechnology - פילוחים אנליטיים ומדדי מפתח (LIXT)

Capital must distinguish fundamental growth from short-term speculation. The Lixte Biotechnology (LIXT) model, which outsources testing to external CRO partners, minimizes costs while maintaining control over patents. By analyzing the LTM sales growth YoY, an investor can see the percentage increase in revenue over a trailing twelve-month period. Daily data tracking on this chart allows for the immediate identification of abnormal spikes or trend reversals, confirming the actual resilience of the business's revenue.